Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Tu

Showing results (251-260 of 321) with videos related to

Pageof 33
Sort By:
BMC Medicine|June 1, 2022
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastasesMei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, et al.
Clinical Lung Cancer|October 18, 2024
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R MutationQing Zhou, Jie Li, Shun-Dong Cang, et al.
Frontiers in Pharmacology|July 26, 2018
Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary FibrosisChristine R Keenan, Shenna Y Langenbach, Fernando Jativa, et al.
Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.
Clinical Lung Cancer|June 20, 2025
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)Jia-Xin Lin, Qing Zhou, Hong-Hong Yan, et al.
Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Science Bulletin|January 20, 2023
The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challengeYi-Chen Zhang, Qing Zhou, Zhi-Hong Chen, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancerSi-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
Pageof 33

Showing results (251-260 of 321) with videos related to

Sort By:
Pageof 33
BMC Medicine|June 1, 2022
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastasesMei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, et al.
Clinical Lung Cancer|October 18, 2024
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R MutationQing Zhou, Jie Li, Shun-Dong Cang, et al.
Frontiers in Pharmacology|July 26, 2018
Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary FibrosisChristine R Keenan, Shenna Y Langenbach, Fernando Jativa, et al.
Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.
Clinical Lung Cancer|June 20, 2025
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)Jia-Xin Lin, Qing Zhou, Hong-Hong Yan, et al.
Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Science Bulletin|January 20, 2023
The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challengeYi-Chen Zhang, Qing Zhou, Zhi-Hong Chen, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancerSi-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
Pageof 33